T. Rowe Price Associates
EVFM

T. Rowe Price Associates’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

T. Rowe Price Associates’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,422
Closed -$232K – 2887
2020
Q4 		$232K Sell
6,422
-945
-13% -$34.2K ﹤0.01% 2519
2020
Q3 		$261K Buy
+7,367
New +$320K ﹤0.01% 2340

Other funds holding EVFM

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
GLA
Great Lakes Advisors Chicago, Illinois $12.1B AUM 29.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates's EVFM Position: Q1 2021 in Review

T. Rowe Price Associates sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q1 2021, closing a stake of 6,422 shares — an estimated $232K sold.

T. Rowe Price Associates first reported a position in EVFM in Q3 2020 and held it in 2 quarters. The position peaked at $261K in Q3 2020. 103 funds tracked by Wall St. Rank hold EVFM as of Q1 2021.

  • T. Rowe Price Associates reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 6,422 Evofem Biosciences, Inc. Common Stock shares in Q1 2021, an estimated $232K.
  • T. Rowe Price Associates first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • T. Rowe Price Associates's Evofem Biosciences, Inc. Common Stock position peaked at $261K in Q3 2020.
  • 103 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q1 2021.

Based on T. Rowe Price Associates's 13F filing for Q1 2021, filed 17 May 2021.